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Abstract: Pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose−2-alkylsulfanyl-
1,3-oxazoline (Glc-PSO) structure exhibit an unprecedented specificity as inhibitors of 
mammalian β-glucosidase. Notably, their inhibitory potency against human β-
glucocerebrosidase (GCase) was found to be strongly dependent on the nature of aglycone-
type moieties attached at the sulfur atom. In the particular case of ω-substituted hexadecyl 
chains, an amazing influence of the terminal group was observed. A comparative study on a 
series of Glc-PSO derivatives suggests that hydrogen bond acceptor functionalities, e.g. fluoro 
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or methyloxycarbonyl, significantly stabilize the Glc-PSO:GCase complex. The S-(16-
flurohexadecyl)-PSO glycomimetic turned out to be a more potent GCase competitive inhibitor 
than ambroxol, a non glycomimetic drug currently in pilot trials as a pharmacological chaperone 
for Gaucher disease. Moreover, the inhibition constant increase by one order of magnitude 
when shifting from neutral (pH 7) to acidic (pH 5) media, a favorable characteristic for a 
chaperone candidate. Indeed, the fluoro-PSO derivative also proved superior to ambroxol in 
mutant GCase activity enhancement assays in N370S/N370S Gaucher fibroblasts. The results 
represent a proof of concept of the potential of exploiting long-range non-glycone interactions in 
glycosidase inhibitor/chaperone design. 
 
Highlights 
· Glucopyranose−2-alkylsulfanyl-1,3-oxazolines are selective inhibitors of β-glucosidase. 
· Binding to human β-glucocerebrosidase strongly depends on aglycone-type interactions. 
· Structure-activity relationship studies point to long-range favorable contacts. 
· Incorporation of H-bond acceptor groups in a S-hexadecyl chain was found favorable. 
· New pharmacological chaperones for Gaucher disease have been identified. 
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Introduction 
 
The search for compounds capable of modulating the activity of glycosidases, the enzymes that 
catalyze the hydrolysis of the glycosidic bond in polysaccharides and glycoconjugates, 
represents one of the more active research fields in glycobiology [1]. Glycosidase inhibitors are 
fundamental tools to interrogate biological processes involving biosynthesis, metabolism and 
recognition of carbohydrates [2] and bear strong potential for the development of drugs against 
associated pathologies [3], including cancer [4-8], diabetes [9,10], infection [11-13], ischemia 
[14] or neurodegenerative diseases [15,16]. On the other hand, compounds stabilizing the 
proper folding of trafficking-incompetent mutant glycosidases at the endoplasmid reticulum 
(ER), thereby rescuing them from degradation by the quality control system of the cell, show 
high promise as pharmacological chaperones for the treatment of lysosomal storage disorders 
[17-21] such as Gaucher [22-27], Fabry [28-30] or GM1 gangliosidosis [31-34], formally acting as 
effectors of the corresponding dysfunctional enzyme. Someway counterintuitively, the 
glycosidase inhibitory and chaperoning activities often coexist, the balance between them being 
a function of concentration and relative binding affinities at neutral (ER) and acidic pH 
(lysosome) [35]. 
With few exceptions [36-40], most naturally occurring or de novo synthesized glycosidase 
inhibitors/chaperones are carbohydrate-like derivatives (glycomimetics) in which the acetal 
group characteristic of glycosides has been modified while preserving a hydroxylation pattern of 
stereochemical complementarity with the aglycone moiety of the putative glycosidase substrate. 
Yet, recent work has shown the importance of implementing non-glycone interactions to achieve 
glycosidase selectivity levels within isoenzymes compatible with clinical applications [41-47]. 
Most of the work in this sense has focused on nitrogen- (iminosugars [48,49],16 sp2-iminosugars 
[50-58], azasugars [59,60]) and carbon-in-the-ring (carbasugars [61,62], cyclitols [63,64]) 
carbohydrate mimics. Surprisingly, aglycon effects for glycomimetics keeping the pyranose core 
intact have been much less studied [65-68], even though modifications at the glycosidic region 
has the potential to be compatible with molecular diversity-oriented strategies with a relatively 
low synthetic cost [69]. 
In a previous report [70], we developed a new family of pyranoid-type glycomimetics having a 
cis-1,2-fused glucopyranose−2-alkylsulfanyl-1,3-oxazoline structure (Glc-PSO, Figure 1) 
behaving as selective β-glucosidase inhibitors. PSO derivatives can be formally considered as 
conformationally locked N-glycosides, which warrant chemical and enzymatic stability. Their 
fused six-membered―five-membered bicyclic skeleton, analogous to that of the potent O-(N-
acetylglucosaminidase) inhibitors NAG-thiazoline, NButGT and thiamet-G [71] (Figure 1), 
imposes a skew-boat conformation to the pyranose ring, which has been found to impart 
glycosidase transition state mimic character [72]. Structure-chaperone activity relationship 
studies on fibroblasts from Gaucher disease patients evidenced a strong impact of the nature of 
exocyclic S-substituents of Glc-PSO glycomimetics on the mutant lysosomal β-glucosidase (β-
glucocerebrosidase; GCase) effector abilities. Notably, the S-(16-hydroxyhexadecyl) derivative 
(Glc-PSO-HHD) was as efficient as the non-glycomimetic chaperone candidate ambroxol (ABX), 
currently in pilot trials in humans [73], for the N370S homozygous GCase mutation, the most 
prevalent for this lysosomal storage disorder. The possibility of hydrogen bonding involvement 
of the terminal hydroxyl group, once the pyranoid ring sits in the active site of the enzyme, with 
an amino acid residue located at an appropriate distance was advanced. To test this 
hypothesis, we have now expanded the PSO family with the preparation of a series of 
analogues keeping the hexadecyl chain in the aglycone but modifying the terminal group or the 
configuration of the core. The synthetic strategy and the evaluation of the new compounds as 
glycosidase inhibitors and chaperone candidates are reported. 
 
 
 
Figure 1. General structure of Glc-PSO glycomimetics, structures of the related glycosidase 
inhibitors NAG-thiazoline, NBuGT and thiamet-G and structure of the previously reported Glc-
PSO derivative Glc-PSO-HHD, which exhibited pharmacological chaperone abilities towards 
human glucocerebrosidase in Gaucher disease fibroblasts. 
 
Results 
 
The preparation of PSO glycomimetics with a hydroxylation profile matching that of D-glucose 
and differing in the S-linked aglycon portion relies on the S-alkylation reaction of the pivotal 1,3-
oxazolidine-2-thione glucopyranose intermediate 1. Taking into consideration that the target 
enzyme GCase has been shown to exhibit low discriminating capabilities between active site-
binding ligands differing in the configuration at C-4 for some glycomimetic families [74], the 
corresponding D-galacto configured epimer 2 was also initially considered. The methodology 
used for the synthesis of 1 and 2 starts from tri-O-acetyl-D-glucal (3) or -D-galactal (5), 
respectively, and involved epoxidation of the double bond with in situ generated 
dimethyldioxirane. In the first case, the reaction afforded a mixture of the α-D-gluco-and β-D-
manno-configured tri-O-acetyl-1,2-anhydrosugars 4 (D-gluco/D-manno ratio 7:1) in 90 % yield 
[75]. Epoxidation of 5 provided instead exclusively the α-epoxide 6 (α-D-galacto configuration) in 
an almost quantitative yield [75]. Reaction of 4 and 6 with potassium thiocyanate and catalytic 
amounts of TiO(CH3CO2)2  led to the requested thionocarbamates 1 and 2 in 87 and 79% yield, 
respectively [76,77] (Scheme 1). 
 
 
 
Scheme 1. Synthesis of 1,3-oxazolidine-2-thione glycopyranose derivatives 1 and 2. 
 
In view of the good GCase chaperon properties observed for the D-gluco-PSO derivative 
bearing an S-(ω-hydroxyhexadecyl) aglycon moiety Glc-PSO-HHD (Figure 1) and the significant 
contribution of the terminal hydroxyl to this behaviour [70], in this work we have chosen to 
examine the incorporation of a series of ω-substituted hexadecyl chains bearing different 
terminal groups, including ester, carboxylic acid, iodo and fluoro. These compounds were 
prepared using the corresponding distal iodo derivatives as the alkylating agents. Methyl 16-
iodohexadecanoate and 16-iodohexadecanoic acid were prepared from the corresponding 
commercially available 16-bromo derivatives by reaction with sodium iodide in acetone (see 
Supporting Information). Given the ambident character of the thionocarbamate functionality [78], 
the reaction conditions for the alkylation step had to be carefully adjusted in order to warrant the 
alkylation reaction regioselectively at the sulfur atom. Thus, compound 1 was treated with a 
series of different alkyl iodides in dichloromethate in the presence of triethylamine and N,N-
dimethylaminopyridine (DMAP) following the work by Rollin et al. [79,82]. Reactions carried out 
under these soft conditions afforded the expected acetyl-protected PSO derivatives 7-10 in 52-
87 % yields (Table 1). Interestingly, reaction of 1 with 1,16-diiodohexadecane not only afforded 
the expected S-(16-iodohexadecyl)sulfanyl derivative 8, but also the dialkylation product 9, 
isolated in 32 % yield (Table 1, entry 2). We also prepared the corresponding D-galacto-PSO 
derivative 11, bearing the S-(16-hydroxyhexadecyl) antenna, to test the effect of the 
configurational change on the inihibitory/chaperone properties. 
The S-alkyl character of compounds 7-11 was confirmed by 13C NMR spectroscopy: the 
chemical shift for the quaternary sp2 carbon atom at position 2 in the five-membered heterocycle 
varied from roughly 190 ppm (-N-C=S in 1,3-oxazolidine-2-thiones 1 and 2) to approximately 
170 ppm (-N=C-SR in PSO derivatives 7-11). This data is in accordance with analogous 
thionocarbamates already reported in the literature [70]. 
The target fully-unprotected PSOA-glycomimetics 12-16 were obtained in 81-100 % yield by 
final removal of the acetyl protecting groups using methanol under standard NaOMe-catalyzed 
conditions. In order to obtain derivative 17, precursor 7 was treated with a solution of sodium 
hydroxide in methanol under similar reactions conditions (Table 1, entry 2). The vicinal proton-
proton coupling constants about the pyranose ring both for the acetylayed (7-11) and the 
unprotected (12-17) PSO derivatives were in agreement with a skew-boat conformation close to 
0S2 as previously observed for us [70] and others [83,84] in structurally related bicyclic cis-1,2-
fused glucopyranose structures in solution. 
 
Table 1. Synthesis of 2-S-alkylsulfanyl-1,3-oxazoline D-glycopyranose derivatives. 
 
    S-alkylationa O-deprotectionb 
Entry Starting M. Alkyl Halide Product Yield (%) Product Yield (%) 
 
95 
1 1  
 
52 
 
81 
 
64 
 
100 
2 1 
 
 
32 
 
94 
3 1  
 
87 
 
70 
4 2 
 
 
89 
 
90 
aCarried out at rt during 24 h with 1.0 eq. substrate, 3.0 eq. alkyl halide, 3.0 eq. Et3N and 2 mol% DMAP 
in CH2Cl2. bCarried out at rt during 12 h with 1.0 eq. of S-alkylated substrate and 5 mol% MeONa in 
MeOH.  
 
Biological evaluation 
 
The new PSO derivatives 12-17 were first screened as inhibitors against a panel of commercial 
glycosidases including α-glucosidase (yeast), β-glucosidase (β-Glcase; almonds and bovine 
liver, cytosolic), α-mannosidase (Jack bean), β-mannosidase (Helix pomatia), trehalase (pig 
kidney), amyloglucosidase (Aspergillus niger), naringinase (β-glucosidase/α-L-rhamnosidase, 
Penicillium decumbens), α-galactosidase (green coffee beans), β-galactosidase (E. coli), and 
amyloglucosidase (Aspergillus niger). All compounds behaved as competitive inhibitors of the 
mammalian β-Glcase and exhibited total selectivity within the series of enzymes assayed; a 
unique signature of the PSO family whose molecular basis is still unknown. The corresponding 
inhibition constants (Ki) at the optimal pH of β-Glcase (7.3) ranged from 5.5 to 26.4 μM (Table 
2), similar to that previously encountered for Glc-PSO-HHD (12 μM) [70]. Interestingly, the 
inhibition potency decreased from 2 to 11-fold when moving from pH 7.3 to 5.5, suggesting that 
the neutral form of the compounds is the most active species. 
 
 
Table 2. Ki Values (μM) against Bovine Liver (Cytosolic) β-Glucosidasea and IC50 Values (μM) 
against Human GCase for Compounds 12-17. 
Enzyme  pH 12 13 14 15 16 17 
β-Glcase 
(bovine liver) 
7.3 26.4 19.3 11.8 11.1 5.5 22.6 
β-Glcase 
(bovine liver) 
5.5 45 98 139 66 62 61 
GCase 
(Homo 
sapiens) 
7.0 33 230 NIb 3.9 NI 420 
GCase 
(Homo 
sapiens) 
5.0 300 >1000 NI 27 NI >1000 
aInhibition was competitive in all cases. No inhibition was observed for any of the compounds at 
2 mM on almonds β-glucosidase, yeast α-glucosidase, jack bean α-mannosidase, Helix pomatia 
β-mannosidase, pig kidney trehalase, Aspergillus niger amyloglucosidase, Penicillium 
decumbens naringinase, green coffee α-galactosidase, E. coli β-galactosidase, or yeast 
isomaltase. bNI: no inhibition observed at 1 mM. 
 
Inhibition of bovine liver β-glucosidase is often used as a preliminary parameter to select 
candidates as pharmacological chaperones for mutant human GCase associated with Gaucher 
disease. Yet, the predictive character of the data must be taken with care: although both 
enzymes are members of the GHA clan in the CAzY classification [85], meaning that they share 
three-dimensional structural similarities, they belong to different glycosyl hydrolase families, 
namely GH1 and GH30, with only limited sequence similarity [85]. Indeed, determination of the 
inhibition activity against human GCase (pH 7.0) revealed that the D-Gal-PSO representative 16 
was inactive, whereas a strong influence of the terminal functional group at the hexadecyl 
aglycone chain was observed in the Glc-PSO series, the inhibitory potency decreasing in the 
sense F (15; IC50 3.9 μM) > COOMe (12; IC50 33 μM) > I (13; IC50 230 μM) > COOH (17; IC50 
420 μM). The dimeric derivative 14 turned out to be inactive (Table 2). No inhibition of other 
lysosomal enzymes, such as α-glucosidase, α-galactosidase, β-galactosidase, and β-
hexosaminidase, was observed, reproducing the selectivity pattern already found in commercial 
enzymes. Most interestingly, an about one-order-of-magnitude decrease in the GCase inhibiton 
strength was also observed at pH 5 (Table 2; see also Figure 2 for the most active compounds 
15 and 12), a favorable feature for chaperone candidates. 
‐log [conc. (M)]
G
Ca
se
ac
ti
vi
ty
 (%
 c
on
tr
ol
) 15 (pH 7)
15 (pH 5)
12 (pH 7)
12 (pH 5)
 
Figure 2. Effects of the PSO derivatives 15 and 12 on GCase activity in lysate from human 
normal fibroblasts as a function of pH. Enzyme activity in normal cell lysates was determined in 
the absence or presence of increasing concentrations of the chaperones. Each point represents 
the mean of triplicate determinations obtained in a single experiment. Values were expressed 
relative to the activity in the absence of compounds (100%). 4-Methylumbelliferyl β-D-
glucopyranoside was used as substrate. 
 
The dramatic effect of the ω-substituent in the hexadecyl chain on the ability of PSO derivatives 
to inhibit GCase, above two orders of magnitude when comparing the fluoro and the carboxylic 
acid groups, reinforces our initial hypothesis that PSO:GCase complexes might be stabilized by 
a long-range interaction involving this terminal group and an amino acid residue located at a 
maximum distance of 22 Å from the catalytic site (Figure 3). Comparing with Glc-PSO-HHD 
(IC50 11.2 μM) [70], where the ω-substituent is OH, only the fluoro (15) and methoxycarbonyl 
(12) derivatives exhibit comparable binding affinities, much higher that the iodo (13) or 
carboxylic acid (17) partners. It is interesting to speculate that the terminal group is acting as 
hydrogen bond acceptor and that optimizing this long-range hydrogen bonding interaction may 
provide a general strategy for the design of potent and specific GCase inhibitors/chaperones. 
The IC50 value for 15 is even lower as compared to that encountered for the reference 
chaperone drug ambroxol against GCase in a similar assay (4.1 μM) [70]. 
 
 
Figure 3. 3D Molecular model of Glc-PSO-HDD (carbons in grey, oxygens in red, nitrogen in 
light blue, sulfur in yellow; hydrogens have been omitted for the sake of clarity). The pyranose 
ring is in a 0S2 coformation and the hexadecyl chain has been set to the more stable extended 
conformation. The distance between the anomeric nitrogen atom and the terminal substituent in 
the chain, which remains identical in all the new PSO derivatives prepared in this work, is 
indicated. 
 
Compounds 12 and 15 were selected for further enzyme activity enhancement assays in 
healthy and Gaucher fibroblasts from patients having the N370S/N370S or the L444P/L444P 
mutations. The first one, the most common mutation among Gaucher patients, is located in the 
catalytic domain of the enzyme, while the second one is located in a noncatalytic domain. The 
cells were cultured for 5 days in the absence and in the presence of various concentrations of 
12 or 15, then lysed and the β-glucocerebrosidase activity determined using 4- 
methylumbelliferyl β-D-glucopyranoside as substrate.  
In normal cells, 12 and 15 had no effect on GCase activity. In N370S/N370S Gaucher 
fibroblasts (Figure 4) compound 12 had only a marginal effect (12% activity increase at 30 μM 
concentration), whereas 15 up-regulated the activity of the mutant enzyme in a very significant 
manner (62% at 30 μM), actually more efficiently than the hydroxyl-bearing analogue Glc-PSO-
HHD (55% at 90 μM). In a parallel assay, ABX led to a maximum activity enhancement of 33% 
at 10 μM [70], with a decrease in the chaperone efficiency when increasing the concentration to 
30 μM, meaning that the inhibitory activity overcomes the chaperone effect. In the case of 15, 
this situation occurred only at 60 μM, indicating a more favorable chaperone/inhibitor balance. 
Neither 12 or 15 nor ABX or Glc-PSO-HHD were effective at increasing the activity in the case 
of the L444P/L444P mutant GCase, nor did they exhibit toxic effect on any of the normal or 
mutant cell lines assayed for 5 days of incubation. 
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Figure 4. Effect of PSO glycomimetics 12 and 15 in GCase activity in N370S/N370S fibroblasts. 
Fibroblasts from patients were cultured in the absence or presence of the indicated 
concentrations of the chaperone for 96 h and the GCase activities in lysates were measured 
using 4-methylumbelliferyl β-D-glucopyranoside as substrate. Each bar represents the mean ± 
SEM of three determinations each done in triplicate. The asterisks indicate highly significant 
statistical difference (p < 0.01) from the values in the absence of the compound (t test). 
 
The ensemble of results supports the potential of the PSO scaffold for the design of selective β-
Glc inhibitors and active site-directed pharmacological chaperones for Gaucher disease. 
Although the observed activity enhancements do not surpass the values reported for the most 
efficient iminosugar-type chaperones [86], they are in principle medically useful. Most 
importantly, they also provide a proof of concept that long-range non-glycone interactions can 
be advantageously exploited to endow a rigid pyranoid glycone moiety with high binding affinity 
and selectivity toward a given glycosidase and suggest a key structural element for the design 
of GCase chaperones. The current data also validate the synthetic methodology for the purpose 
of structure-activity relationship studies and pharmacological chaperone optimization.  
 
Experimental section  
 
General methods. All chemicals were reagent grade and used as supplied unless otherwise 
specified. TiO(CF3COO)2 catalyst was prepared following a previously reported procedure [87]. 
1H and 13C NMR spectra were recorded on a Varian Mercury VX 400 (400 MHz and 100.6 MHz 
respectively) and Varian 400-MR spectrometer in CDCl3 or CD3OD as solvents, with the solvent 
resonance (δ) as the internal standard (CDCl3 δ 7.26 ppm for 1H, δ 77.23 ppm 13C; CD3OD δ 
3.31 ppm for 1H, δ 49.14 ppm for 13C) or using Me4Si as an internal reference (δ 0.00 ppm for 1H 
and 13C). 2D correlation spectra (gCOSY, NOESY, gHSQC, gHMBC) were visualized using the 
VNMR program (Varian). ESI-MS was run on an Agilent 1100 Series LC/MSD instrument. 
Melting points (Mp) were measured on a Melting point apparatus Griffin and are uncorrected. 
Optical rotations were measured at 598 nm at room temperature in a Perkin-Elmer 241 MC 
apparatus with 10 cm cells. IR spectra were recorded on a JASCO FT/IR-600 plus Fourier 
Transform Infrared Spectrometer ATR Specac Golden Gate in the Servei de Recursos Científics 
(SRCiT-URV). Reactions were monitored by TLC carried out on 0.25 mm E. Merc Silica gel 60 
F254 glass or aluminium plates. The plates were visualized under a short-wave UV lamp (250 
nm) or after dipping in a suitable developing solution. Flash column chromatography was 
carried out using forced flow of the indicated solvent on Fluka or Merck Silica gel 60 (230-400 
mesh). Radial chromatography was performed on 1 or 2 mm plates of Kieselgel 60 PF254 silica 
gel, depending on the amount of product. 
 
General procedure for the preparation of the 1,2-anhydrosugars 4 and 6 [75]. The 
corresponding glycal 3 or 5 (1.00 mmol) was dissolved in an ice bath cooled biphasic solution of 
CH2Cl2 (4 mL), acetone (0.4 mL) and saturated aqueous NaHCO3 (6.5 mL). The mixture was 
vigorously stirred and a solution of Oxone® (1.23 g, 2.00 mmol) in H2O (5 mL) was added 
dropwise over 15 min. The crude reaction was vigorously stirred at 0º C for 30 min and then 
allowed to warm to room temperature until complete consumption of the glycal (TLC 
monitoring). The organic phase was separated and the aqueous phase was extracted with 
CH2Cl2 (2 x 4 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated to afford the 1,2-anhydro-pyranoses 4 (90 %, mixture D-gluco/D-manno 7:1) or 6 
(98 %, only α-epoxide). The crude could not be purified due the inherent instability of 1,2-
anhydrosugars. 
 
General procedure for the synthesis of cis-1,2-fused 1,3-oxazolidine-2-thione precursors 
1 and 2 [76,77]. To a stirred solution of the crude 1,2-anhydro-sugar 4 or 6 (1.00 mmol) and 
KSCN (3.00 mmol) in dry CH3CN (5 mL), finely powdered TiO(CF3COO)2 (0.02 mmol) was 
added under an Ar atmosphere, and the mixture was heated to boiling for appropriate time. 
After completion of the reaction (TLC monitoring), the mixture was cooled to room temperature, 
H2O (10 mL) was added and the resultant mixture was extracted with EtOAc (2 x 20 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated. Flash 
chromatography on silica gel (ethyl acetate/hexanes 2:1) gave the bycyclic derivatives 1 or 2 
(87 % and 79 %, respectively). 
 
General procedure for the S-alkylation of cis-1,2-fused D-glycopyranose―1,3-
oxazolidine-2-thione derivatives. To a solution of the 1,3-oxazolidine-2-thione derivative (1.00 
mmol) in CH2Cl2 (3.5 mL), the corresponding alkyl iodide (3.00 mmol), Et3N (3.00 mmol) and 
TBD (0.2 mmol) were added followed by stirring at room temperature. After completion of the 
reaction, the mixture was washed with saturated NaHCO3 and brine, dried, and concentrated. 
Chromatographic purification afforded the S-alkylated compounds in the yields shown. 
 
General procedure for acetyl deprotection of cis-1,2-fused D-glycopyranose―2-
alkylsulfanyl-1,3-oxazoline derivatives. Sodium methoxide (0.05 mmol) was added to a 
solution of protected 1,3-oxazoline carbohydrate (1.00 mmol) in methanol (20 mL), followed by 
stirring at room temperature. Upon completion of the reaction, the solvent was removed in 
vacuo, and the crude product was purified by flash chromatography on silica gel to afford the 
deprotected compounds in the yields shown. 
 
3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-galactopyranoside[1,2-d]-1,3-oxazolidine-2-thione (2).  
The title compound was prepared following the general procedure for the synthesis of cis-1,2-
fused 1,3-oxazolidine-2-thione carbohydrate derivatives starting from 6 (810 mg, 2.81 mmol), 
KSCN (642 mg, 8.43 mmol), TiO(CF3COO)2 (16.6 mg, 0.06 mmol) in dry CH3CN (14 mL). The 
reaction mixture was stirred under reflux for 2,5 h. Standard workup, followed by flash 
chromatography on silica gel (2:1 AcOEt/hexane), afforded 2 (776 mg, 79% yield) as a white 
solid. Data: Rf (4:1 AcOEt/hexane): 0.56. Mp: 52-55 ºC. [α]D + 46.5 (c 1.38, CHCl3). FT-IR (neat) 
υ in cm-1: 3301, 2923, 2853, 1743, 1490, 1368, 1225, 1174, 1033. 1H NMR (400 MHz, CDCl3) δ 
in ppm: 8.41 (bs, 1H, =NH); 5.75 (d, 1H, J1,2= 6.0 Hz, H-1); 5.56 (pt, 1H, J4,3 = 3.2 Hz, J4,5= 3.6 
Hz, H-4); 5.17 (dd, 1H, J3,2= 6.6 Hz, J3,4= 3.2 Hz, H-3); 4.85 (pt, 1H, J2,1= 6.0 Hz, J2,3= 6.6 Hz, H-
2); 4.37 (ddd, J4,5= 3.6 Hz, J5,6= 7.4 Hz, J5,6’ = 5.8 Hz, 1H, H-5); 4.25 (dd, J6,5= 7.4 Hz, J6,6’= 11.6 
Hz, H-6); 3.99 (dd, J6’,5= 5.8 Hz, J6’,6= 11.6 Hz, H-6’); 2.11 (s, 3H, AcO); 2.08 (s, 3H, AcO); 2.05 
(s, 3H, AcO). 13C NMR (100.6 MHz, CDCl3) δ in ppm: 189.8 (C=S); 170.9, 169.9, 168.7 (C(O), 
AcO); 82.1 (C-1); 81.0 (C-2); 70.7 (C-3); 70.4 (C-5); 66.2 (C-4); 60.6 (C-6); 20.8, 20.7, 20.6 
(CH3, AcO). +TOF MS Calcd for C29H49NO9S m/z [M-Na]+: 610.3020, found: 610.3039. 
 
3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoside[1,2-d]-16-
methoxycarbonylhexadecylsulfanyl-1,3-oxazoline (7). The title compound was prepared 
following the general procedure for the S-alkylation of cis-1,2-fused 1,3-oxazoline carbohydrate 
derivatives starting from 1 (41.3 mg, 0.12 mmol), methyl 16-iodo hexadecanoate (141.4 mg, 
0.36 mmol), Et3N (52 μL, 0.36 mmol), TBD (0.4 mg, 3 μmol) and CH2Cl2 (1.5 mL). The reaction 
mixture was stirred at rt for 24 h. After standard workup, the crude was purified by flash 
chromatography (from 1:10 to 2:1 AcOEt/hexane) followed by recrystallization from AcOEt-
Hexane to afford compound 7 (38.1 mg, 52% yield) as a white solid. Data: Rf (1:1 
AcOEt/hexane): 0.74. Mp: 67-68 ºC. [α]D +44.8 (c 3.13, CHCl3). FT-IR (neat) υ in cm-1: 2917, 
2851, 1734, 1602, 1372, 1218, 1110, 1045, 1034, 1012, 883. 1H NMR (400 MHz, CDCl3) δ in 
ppm: 5.86 (d, 1H, J1,2= 7.5 Hz, H-1); 5.18 (t, 1H, J3,2= J3,4= 4.1 Hz, H-3); 4.90 (dd, 1H, J4,3= 4.1 
Hz, J4,5= 8.1 Hz, H-4); 4.50 (ddd, 1H, J2,1= 7.5 Hz, J2,3= 4.0 Hz, J2,4= 0.8 Hz, H-2); 4.26 (dd, 1H, 
J6,5= 5.5 Hz, J6,6’= 12.2 Hz, H-6); 4.15 (dd, 1H, J6’,5= 3.1 Hz, J6’,6= 12.2 Hz, H-6’); 3.67 (ddd, J5,4= 
8.1 Hz, J5,6= 5.5 Hz, J5,6’ =3.1 Hz, 1H, H-5); 3.64 (s, 3H, MeO); 3.04 (t, 2H, J= 7.4 Hz, CH2-S 
aliph); 2.28 (t, 2H, J= 7.8 Hz, CH2-C(O) aliph); 2.10 (s, 3H, AcO); 2.06 (s, 3H, AcO); 2.05 (s, 3H, 
AcO); 1.69 (quint, 2H, J= 7.5 Hz, CH2 aliph.); 1.59 (quint, 2H, J= 7.4 Hz, CH2 aliph.); 1.38 (quint, 
2H, J= 7.3 Hz, CH2 aliph.); 1.35-1.22 (20H, CH2 aliph.). 13C NMR (100.6 MHz, CDCl3) δ in ppm: 
174.6 (C=N); 171.2, 170.9, 169.8, 169.5 (C(O), AcO); 92.5 (C-1); 77.1 (C-2); 70.2 (C-3); 68.1 
(C-4); 67.5 (C-5); 63.5 (C-6); 51.6 (MeO); 34.3 (CH2-C(O)); 32.4 (CH2-S); 29.8, 29.8, 29.8, 29.7, 
29.6, 29.5, 29.3, 29.3, 28.9, 25.1 (CH2 aliph); 21.0, 21.0, 20.9 (CH3, AcO). +TOF MS Calcd for 
C30H49NO10S m/z [M-Na]+: 638.2969, found: 638.2976. 
 3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoside[1,2-d]-(16-iodohexadecyl)sulfanyl-1,3-
oxazoline (8) and 1,16-Di(3,4,6-tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoside[1,2-d]-1,3-
oxazolidine-2-thione)hexadecane (9). The title compounds were prepared following the 
general procedure for the S-alkylation of cis-1,2-fused 1,3-oxazoline carbohydrate derivatives 
starting from 1 (37.3 mg, 0.10 mmol), 1,16-diiodohexadecane (130 mg, 0.27 mmol), Et3N (38 
μL, 0.27 mmol), TBD (0.3 mg, 2 μmol) and CH2Cl2 (0.5 mL). The reaction mixture was stirred at 
rt for 24 h. After standard workup, the crude was purified by flash chromatography (from 1:9 to 
1:2 AcOEt/hexane) to afford 8 (48.4 mg, 64 % yield) as a colourless syrup and 9 (31.6 mg, 32 % 
yield) as an off-white syrup. Data for 8: Rf (1:1 AcOEt/hexane): 0.78. [α]D +41.9 (c 0.82, CHCl3). 
FT-IR (neat) υ in cm-1: 2922, 2852, 1745, 1592, 1461, 1367, 1222, 1147, 1110, 1038. 1H NMR 
(400 MHz, CDCl3) δ in ppm: 5.89 (d, 1H, J1,2= 7.4 Hz, H-1); 5.2 (pt, 1H, J3,2= 3.8, J3,4= 4.2 Hz, H-
3); 4.93 (ddd, 1H, J4,2= 0.8 Hz, J4,3= 4.2 Hz, J4,5= 8.8 Hz, H-4); 4.52 (ddd, 1H, J2,1= 7.4 Hz, J2,3= 
3.8 Hz, J2,4=0.8 Hz, H-2); 4.29 (dd, 1H, J6,5= 5.2 Hz, J6,6’=12.2 Hz, H-6); 4.18 (dd, 1H, J6’,5= 2.8 
Hz, J6’,6=12.2 Hz, H-6’); 3.70 (m, 1H, H-5); 3.19 (t, 2H, J= 7.0 Hz, CH2-I); 3.06 (t, 2H, J= 7.4 Hz, 
CH2-S); 2.12 (s, 3H, AcO); 2.09 (s, 3H, AcO); 2.07 (s, 3H, AcO); 1.82 (quint, 2H, J= 7.2 Hz, CH2 
aliph); 1.72 (quint, 2H, J= 7.4 Hz, CH2 aliph); 1.41-1.20 (24H, CH2 aliph). 13C NMR (100.6 MHz, 
CDCl3) δ in ppm: 171.2 (C=N); 170.9, 169.8, 169.6 (C(O), AcO); 92.5 (C-1); 77.1 (C-2); 70.2 (C-
3); 68.0 (C-4); 67.4 (C-5); 63.5 (C-6); 32.4 (CH2-S); 30.7, 29.9, 29.8, 29.8, 29.8, 29.7, 29.6, 
29.5, 29.3, 28.9, 28.8, 27.0 (CH2 aliph); 21.1, 21.0, 21.0 (CH3, AcO); 7.7 (CH2-I).+TOF MS Calcd 
for C29H48INO8S m/z [M-Na]+: 720.2038, found: 720.2049. Data for 9: Rf (1:1 AcOEt/hexane): 
0.26. [α]D +1.4 (c 3.98, CHCl3). FT-IR (neat) υ in cm-1: 3460, 2923, 2852, 1741, 1590, 1368, 
1224, 1147, 1111, 1038, 752. 1H NMR (400 MHz, CDCl3) δ in ppm: 5.88 (d, 2H, J1,2= 7.4 Hz, 2x 
H-1); 5.2 (pt, 2H, J3,2= 4.0, J3,4= 4.2 Hz, 2x H-3); 4.93 (ddd, 2H, J4,2= 0.8 Hz, J4,3= 4.2 Hz, J4,5= 
8.8 Hz, 2x H-4); 4.52 (ddd, 2H, J2,1= 7.4 Hz, J2,3= 4.0 Hz, J2,4=0.8 Hz, 2x H-2); 4.29 (dd, 2H, 
J6,5= 5.4 Hz, J6,6’=12.2 Hz, 2x H-6); 4.18 (dd, 2H, J6’,5= 2.8 Hz, J6’,6=12.2 Hz, 2x H-6’); 3.69 (m, 
2H, 2x H-5);  3.06 (t, 4H, J= 7.4 Hz, 2x CH2-S); 2.12 (s, 6H, 2x AcO); 2.09 (s, 6H, 2x AcO); 2.07 
(s, 6H, 2x AcO); 1.72 (quint, 4H, J= 7.4 Hz, 2x CH2 aliph); 1.43-1.20 (24H, CH2 aliph). 13C NMR 
(100.6 MHz, CDCl3) δ in ppm: 172.1 (2x C=N); 170.9, 169.8, 169.5 (2x C(O), AcO); 92.5 (2x C-
1); 77.1 (2x C-2); 70.2 (2x C-3); 68.0 (2x C-4); 67.4 (C-5); 63.5 (2x C-6); 32.4 (2x CH2-S); 29.8, 
29.8, 29.8, 29.7, 29.4, 29.3, 28.9 (2x CH2 aliph); 21.0, 21.0, 21.0 (2x CH3, AcO). +TOF MS 
Calcd for C42H64N2O16S2 m/z [M-H]+: 939.3589, found: 939.3565. 
 
3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoside[1,2-d]-(16-fluorohexadecyl)sulfanyl-
1,3-oxazoline (10). The title compound was prepared following the general procedure for the S-
alkylation of cis-1,2-fused 1,3-oxazoline carbohydrate derivatives starting from 1 (50.7 mg, 0.15 
mmol), 1-fluoro-16-iodohexadecane (138 mg, 0.37 mmol), Et3N (52 μL, 0.37 mmol), TBD (0.4 
mg, 0.03 mmol) and CH2Cl2 (0.5 mL). The reaction mixture was stirred at rt for 24 h. After 
standard workup, the crude was purified by flash chromatography (from 1:9 to 1:1 
AcOEt/hexane) to afford compound 10 (74.7 mg, 87 % yield) as an off-white solid. Data: Rf (1:1 
AcOEt/hexane): 0.66. Mp: 51-52 ºC. [α]D +41.8 (c 3.62, CHCl3). FT-IR (neat) υ in cm-1: 2918, 
2850, 1742, 1600, 1464, 1371, 1213, 1141, 1109, 1049. 1H NMR (400 MHz, CDCl3) δ in ppm: 
5.88 (d, 1H, J1,2= 7.4 Hz, H-1); 5.20 (pt, 1H, J3,2= 3.8 Hz, J3,4= 4.2 Hz, H-3); 4.92 (dd, 1H, J4,3= 
4.2 Hz, J4,5= 8.8 Hz, H-4); 4.52 (dd, 1H, J2,1= 7.4 Hz, J2,3= 3.8 Hz, H-2); 4.44 (dt, 2H, J= 6.0 Hz, 
JHF= 47.3, CH2-F aliph); 4.29 (dd, 1H, J6,5= 5.0 Hz, J6,6’=12.0 Hz, H-6); 4.17 (dd, 1H, J6’,5= 2.8 
Hz, J6’,6=12.0 Hz, H-6’); 3.69 (ddd, J5,4= 8.8 Hz, J5,6= 5.0 Hz, J5,6’ =2.8 Hz, 1H, H-5); 3.06 (t, 2H, 
J= 7.4 Hz, CH2-S aliph); 2.12 (s, 3H, AcO); 2.09 (s, 3H, AcO); 2.07 (s, 3H, AcO); 1.77-1.60 (4H, 
CH2 aliph); 1.40-1.20 (24H, CH2 aliph). 13C NMR (100.6 MHz, CDCl3) δ in ppm: 171.1 (C=N); 
170.8, 169.8, 169.5 (C(O), AcO); 92.5 (C-1); 84.4 (d, JCF = 164.6 Hz, CH2-F); 77.1 (C-2); 70.2 
(C-3); 68.0 (C-4); 67.4 (C-5); 63.5 (C-6); 32.4 (CH2-S); 30.7, 30.5, 29.8, 29.8, 29.7, 29.7, 29.7, 
29.7, 29.4, 29.3, 28.9, 25.3, 25.3 (CH2 aliph); 21.0, 21.0, 20.9 (CH3, AcO). 19F NMR (376 MHz, 
CDCl3) δ in ppm: -218.0 (tt, JFH= 47.3 Hz, JFH’= 24.8, CH2-F Hz). +TOF MS Calcd for 
C29H48FNO8S m/z [M-Na]+: 612.2977, found: 612.2986. 
 
3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-galactopyranoside[1,2-d]-(16-
hydroxyhexadecyl)sulfanyl-1,3-oxazoline (11). The title compound was prepared following 
the general procedure for the S-alkylation of cis-1,2-fused 1,3-oxazoline carbohydrate 
derivatives starting from 2 (54.0 mg, 0.16 mmol), 16-iodohexadecanol (172 mg, 0.47 mmol), 
Et3N (66 μL, 0.47 mmol), TBD (0.4 mg, 0.03 mmol) and CH2Cl2 (0.5 mL). The reaction mixture 
was stirred at rt for 24 h. After standard workup, the crude was purified by flash chromatography 
(from 1:10 to 1:3 AcOEt/hexane) to afford compound 11 (89 mg, 91 % yield) as a colourless 
syrup. Data: Rf (1:1 AcOEt/hexane): 0.46. Mp: 32-33 ºC. [α]D +85.5 (c 2.50, CHCl3). FT-IR 
(neat) υ in cm-1: 3410, 2921, 2851, 1747, 1590, 1467, 1369, 1215, 1162, 1117, 1051, 753. 1H 
NMR (400 MHz, CDCl3) δ in ppm: 5.85 (d, 1H, J1,2= 7.1 Hz, H-1); 5.43 (pt, 1H, J4,3= 3.0 Hz, J4,5= 
2.2 Hz, H-4); 4.96 (dd, 1H, J3,2= 7.3 Hz, J3,4= 3.0 Hz, H-3); 4.56 (pt, 1H, J2,1= 7.1 Hz, J2,3= 7.3 
Hz, H-2); 4.22 (pdt, J5,4= 2.2 Hz, J5,6= 7.0 Hz, J5,6’ = 6.6 Hz, 1H, H-5); 4.15 (dt, 1H, J6’,5= 6.6 Hz, 
J6’,6= 11.0 Hz, H-6’); 4.12 (dd, 1H, J6,5= 7.0 Hz, J6,6’=11.0 Hz, H-6’); 3.61 (t, 2H, J= 6.6 Hz, CH2-
OH aliph); 3.03 (m, 2H, CH2-S aliph); 2.11 (s, 3H, AcO); 2.05 (s, 3H, AcO); 2.03 (s, 3H, AcO); 
1.67 (quint, 2H, J= 7.4 Hz, CH2 aliph); 1.61 (bs, 1H, OH); 1.54 (quint, 2H, J= 6.9 Hz, CH2 aliph); 
1.40-1.20 (26H, CH2 aliph). 13C NMR (100.6 MHz, CDCl3) δ in ppm: 170.7 (C=N); 170.7, 170.2, 
170.1 (C(O), AcO); 93.9 (C-1); 77.9 (C-2); 71.7 (C-3); 69.3 (C-5); 66.2 (C-4); 63.1 (CH2-OH); 
61.4 (C-6); 32.9 (CH2 aliph);  32.4 (CH2-S); 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.2, 28.8, 25.9 
(CH2 aliph); 20.9, 20.8, 20.8 (CH3, AcO). +TOF MS Calcd for C29H49NO9S m/z [M-Na]+: 
610.3020, found: 610.3039.  
 
3,4,6-Tri-O-acetyl-1,2-dideoxy-α-D-galactopyranoside[1,2-d]-(16-
hydroxyhexadecyl)sulfanyl-1,3-oxazoline (11). The title compound was prepared following 
the general procedure for the S-alkylation of cis-1,2-fused 1,3-oxazoline carbohydrate 
derivatives starting from 2 (54.0 mg, 0.16 mmol), 16-iodohexadecanol (172 mg, 0.47 mmol), 
Et3N (66 μL, 0.47 mmol), TBD (0.4 mg, 0.03 mmol) and CH2Cl2 (0.5 mL). The reaction mixture 
was stirred at rt for 24 h. After standard workup, the crude was purified by flash chromatography 
(from 1:10 to 1:3 AcOEt/hexane) to afford compound 11 (89 mg, 91 % yield) as a colourless 
syrup. Data: Rf (1:1 AcOEt/hexane): 0.46. Mp: 32-33 ºC. [α]D +85.5 (c 2.50, CHCl3). FT-IR 
(neat) υ in cm-1: 3410, 2921, 2851, 1747, 1590, 1467, 1369, 1215, 1162, 1117, 1051, 753. 1H 
NMR (400 MHz, CDCl3) δ in ppm: 5.85 (d, 1H, J1,2= 7.1 Hz, H-1); 5.43 (pt, 1H, J4,3= 3.0 Hz, J4,5= 
2.2 Hz, H-4); 4.96 (dd, 1H, J3,2= 7.3 Hz, J3,4= 3.0 Hz, H-3); 4.56 (pt, 1H, J2,1= 7.1 Hz, J2,3= 7.3 
Hz, H-2); 4.22 (pdt, J5,4= 2.2 Hz, J5,6= 7.0 Hz, J5,6’ = 6.6 Hz, 1H, H-5); 4.15 (dt, 1H, J6’,5= 6.6 Hz, 
J6’,6= 11.0 Hz, H-6’); 4.12 (dd, 1H, J6,5= 7.0 Hz, J6,6’=11.0 Hz, H-6’); 3.61 (t, 2H, J= 6.6 Hz, CH2-
OH aliph); 3.03 (m, 2H, CH2-S aliph); 2.11 (s, 3H, AcO); 2.05 (s, 3H, AcO); 2.03 (s, 3H, AcO); 
1.67 (quint, 2H, J= 7.4 Hz, CH2 aliph); 1.61 (bs, 1H, OH); 1.54 (quint, 2H, J= 6.9 Hz, CH2 aliph); 
1.40-1.20 (26H, CH2 aliph). 13C NMR (100.6 MHz, CDCl3) δ in ppm: 170.7 (C=N); 170.7, 170.2, 
170.1 (C(O), AcO); 93.9 (C-1); 77.9 (C-2); 71.7 (C-3); 69.3 (C-5); 66.2 (C-4); 63.1 (CH2-OH); 
61.4 (C-6); 32.9 (CH2 aliph);  32.4 (CH2-S); 29.8, 29.8, 29.7, 29.7, 29.6, 29.6, 29.2, 28.8, 25.9 
(CH2 aliph); 20.9, 20.8, 20.8 (CH3, AcO). +TOF MS Calcd for C29H49NO9S m/z [M-Na]+: 
610.3020, found: 610.3039.  
 
1,2-Dideoxy-α-D-glucopyranoside[1,2-d]-16-16-iodohexadecylsulfanyl-1,3-oxazoline (13). 
The title compound was prepared following the general procedure for acetyl deprotection of 
cis-1,2-fused D-glucopyranose―2-alkylsulfanyl-1,3-oxazoline derivatives starting from 8 (30.3 
mg, 0.04 mmol), MeONa (0.2 mg, 3 μmol) and MeOH (1 mL). The reaction mixture was stirred 
at rt for 12 h. After standard workup, the crude was purified by flash chromatography (1:9 
MeOH/CH2Cl2) to afford compound 13 (24.8 mg, 100% yield) as a white solid. Data: Rf (1:9 
MeOH/CH2Cl2): 0.53. Mp: 64-66 ºC. [α]D + 15.0 (c 1.35, CH3OH). FT-IR (neat) υ in cm-1: 3304, 
2915, 2859, 1579, 1469, 1350, 1292, 1163, 1117, 1073, 964. 1H NMR (400 MHz, 2:1 CD3OD/ 
CDCl3) δ in ppm: 5.78 (d, 1H, J1,2= 7.0 Hz, H-1); 4.47 (dd, 1H, J2,1= 7.0 Hz, J2,3= 5.3 Hz, H-2); 
3.78 (dd, 1H, J6’,5= 2.8 Hz, J6’,6=12.0 Hz, H-6’); 3.72 (dd, 1H, J6’,5= 5.2 Hz, J6’,6=12.0 Hz, H-6); 
3.69 (dd, 1H, J3,2= 5.3 Hz, J3,4= 7.0, H-3); 3.47 (dd, 1H, J4,3= 7.0 Hz, J4,5= 8.8 Hz, H-4); 3.32 (m, 
1H, H-5); 3.22 (t, 2H, J= 7.0 Hz, CH2-I); 3.03 (t, 2H, J= 7.4 Hz, CH2-S); 1.79 (quint, 2H, J= 7.2 
Hz, CH2 aliph); 1.71 (quint, 2H, J= 7.4 Hz, CH2 aliph). 1.45-1.28 (24H, CH2 aliph). 13C NMR 
(100.6 MHz, 2:1 CD3OD/ CDCl3 ) δ in ppm: 172.1 (C=N); 93.6 (C-1); 83.4 (C-2); 75.0 (C-5); 74.9 
(C-3); 69.1 (C-4); 62.7 (C-6); 34.5 (CH2 aliph); 32.4 (CH2-S); 31.3, 30.6, 30.5, 30.5, 30.4, 30.0, 
29.5, 29.4 (CH2 aliph); 7.2 (CH2-I). +TOF MS Calcd for C23H42INO5S m/z [M-Na]+: 594.1721, 
found: 594.1701. 
 
1,16-Di(1,2-dideoxy-α-D-glucopyranoside[1,2-d]-1,3-oxazolidine-2-thione)hexadecane (14). 
The title compound was prepared following the general procedure for acetyl deprotection of 
cis-1,2-fused D-glucopyranose―2-alkylsulfanyl-1,3-oxazoline derivatives starting from 9 (31.6 
mg, 0.03 mmol), MeONa (0.1 mg, 2 μmol) and MeOH (1 mL). The reaction mixture was stirred 
at rt for 12 h. After standard workup, the crude was purified by crystallization from MeOH to 
afford compound 14 (21.6 mg, 94% yield) as a white solid. Data: Rf (1:9 MeOH/CH2Cl2): 0.53. 
Mp: 125-126 ºC. [α]D + 19.2 (c 3.10, 2:1 CH3OH/CHCl3). FT-IR (neat) υ in cm-1: 3330, 2919, 
2850, 1743, 1590, 1462, 1352, 1155, 1094, 997. 1H NMR (400 MHz, 2:1 CD3OD/ CD3Cl) δ in 
ppm: 5.78 (d, 2H, J1,2= 7.3 Hz, 2x H-1); 4.47 (dd, 2H, J2,1= 7.3 Hz, J2,3= 5.4 Hz, 2x H-2); 3.79 
(dd, 2H, J6’,5= 3.2 Hz, J6’,6= 12.0 Hz, 2x H-6’); 3.78-3.71 (stack, 3H, 2x H-3 and 2x H-6); 3.52 
(dd, 2H, J4,3= 7.0 Hz, J4,5= 9.0 Hz, 2x H-4); 3.35 (m, 2H, 2x H-5); 3.01 (td, 4H, J= 7.0 Hz, J’= 1.9 
Hz, CH2-S); 1.69 (quint, 4H, J= 7.5 Hz, 2x CH2 aliph); 1.45-1.23 (24H, CH2 aliph). 13C NMR 
(100.6 MHz, 2:1 CD3OD/ CD3Cl) δ in ppm: 172.2 (2x C=N); 93.5 (2x C-1); 83.0 (2x C-2); 74.8 
(2x C-5); 74.4 (2x C-3); 68.9 (2x C-4); 62.4 (2x C-6); 32.4 (2x CH2-S); 30.5, 30.5, 30.4, 30.4, 
30.3, 30.0, 29.5 (2x CH2 aliph). +TOF MS Calcd for C30H52N2O10S2 m/z [M-Na]+: 687.2956, 
found: 687.2904.9. 
 
1,2-Dideoxy-α-D-glucopyranoside[1,2-d]-16-fluorohexadecylsulfanyl-1,3-oxazoline (15). 
The title compound was prepared following the general procedure for acetyl deprotection of cis-
1,2-fused D-glucopyranose―2-alkylsulfanyl-1,3-oxazoline derivatives starting from 10 (44.3 mg, 
0.08 mmol), MeONa (0.2 mg, 5 μmol) and MeOH (1 mL). The reaction mixture was stirred at rt 
for 12 h. After standard workup, the crude was purified by flash chromatography (from 0:1 to 1:9 
MeOH/CH2Cl2) to afford compound 15 (24.3 mg, 70% yield) as a white solid. Data: Rf (1:9 
MeOH/CH2Cl2): 0.53. Mp: 72-73 ºC. [α]D + 21.4 (c 2.25, 2:1 CH3OH/CHCl3). FT-IR (neat) υ in 
cm-1: 3327, 2915, 2850, 1579, 1469, 1162, 1115, 720. 1H NMR (400 MHz, 2:1 CD3OD/CDCl3) δ 
in ppm: 5.76 (d, 1H, J1,2= 7.2 Hz, H-1); 4.43 (dd, 1H, J2,1= 7.2 Hz, J2,3= 5.3 Hz, H-2); 4.39 (dt, 
2H, J= 6.4 Hz, JHF= 41.0, CH2-F aliph); 3.78 (dd, 1H, J6’,5= 3.2 Hz, J6’,6=12.5 Hz, H-6’); 3.74 (dd, 
1H, J6,5= 4.6 Hz, J6,6=12.4 Hz, H-6); 3.70 (dd, 1H, J3,2= 5.3 Hz, J3,4= 7.3, H-3); 3.49 (dd, 1H, 
J4,3= 7.3 Hz, J4,5= 9.2 Hz, H-4); 3.35 (ddd, 1H, J5,4= 9.2 Hz, J5,6= 4.6 Hz, J5,6’= 3.2 Hz, H-5); 2.79 
(m, 2H, CH2-S);  1.715-1.57 (4H, CH2 aliph); 1.40-1.20 (24H, CH2 aliph). 13C NMR (100.6 MHz, 
2:1 CD3OD/CDCl3) δ in ppm: 170.8 (C=N); 92.5 (C-1); 84.0 (d, JCF = 163.0 Hz, CH2-F); 82.1 (C-
2); 73.8 (C-5); 73.6 (C-3); 67.9 (C-4); 61.5 (C-6); 31.5 (CH2-S); 30.3, 30.1 29.4, 29.0, 28.9, 28.4, 
24.9 (CH2 aliph). 19F NMR (376 MHz, CDCl3) δ in ppm: -215.1 (tt, JFH= 41.0 Hz, JFH’= 24.8, CH2-
F Hz). +TOF MS Calcd for C23H42FNO5S m/z [M-Na]+: 486.2660, found: 486.2661. 
 
1,2-Dideoxy-α-D-galactopyranoside[1,2-d]-(16-hydroxyhexadecyl)sulfanyl-1,3-oxazoline 
(16). The title compound was prepared following the general procedure for acetyl deprotection 
of cis-1,2-fused 1,3-oxazoline carbohydrate derivatives starting from 11 (45.2 mg, 0.08 mmol), 
MeONa (0.3 mg, 5 μmol) and MeOH (1 mL). The reaction mixture was stirred at rt for 20 h. After 
standard workup, the crude was purified by recrystallization from MeOH to afford compound 16 
(31.9 mg, 90 % yield) as white crystals. Data: Rf (1:1 AcOEt/hexane): 0.00. Mp: 90-92 ºC. [α]D: 
+31.7 (c 2.73, CH3OH/ CHCl3 2:1). FT-IR (neat) υ in cm-1: 3487, 3299, 2919, 2851, 1744, 1590, 
1468, 1374, 1300, 1161, 1119, 1057, 984. 1H NMR (400 MHz, 1:2 CD3OD/CDCl3) δ in ppm: 
5.60 (d, 1H, J1,2= 7.0 Hz, H-1); 4.34 (pt, 1H, J2,1= 7.0 Hz, J2,3= 6.6 Hz, H-2); 3.75 (dd, 1H, J4,3= 
3.2 Hz, J4,5= 2.0 Hz, H-4); 3.65-3.49 (stack, 3H, H-5, H-6, and H-6’); 3.47 (dd, 1H, J3,2= 6.6 Hz, 
J3,4= 3.2, H-3); 3.35 (t, 2H, J= 7.0 Hz, CH2-OH aliph); 2.80 (m, 2H, CH2-S aliph); 1.50 (quint, 2H, 
J= 7.6 Hz, CH2 aliph); 1.33 (quint, 2H, J= 7.0 Hz, CH2 aliph); 1.25-1.00 (24H, CH2 aliph). 13C 
NMR (100.6 MHz, 1:2 CD3OD/CDCl3) δ in ppm: 170.7 (C=N); 92.8 (C-1); 82.1 (C-2); 73.0 (C-5); 
71.3 (C-3); 67.4 (C-4); 62.1 (CH2-OH); 61.1 (C-6); 32.3 (CH2-S); 31.5, 29.4, 29.4, 29.3, 29.3, 
29.3, 29.0, 28.9, 28.4, 25.6 (CH2 aliph). +TOF MS Calcd for C23H43NO6S m/z [M-Na]+: 
484.2703, found: 484.2704. 
 
1,2-Dideoxy-α-D-glucopyranoside[1,2-d]-16-carboxyhexadecylsulfanyl-1,3-oxazoline (17). 
The title compound was prepared following the general procedure for acetyl deprotection of cis-
1,2-fused D-glucopyranose―2-alkylsulfanyl-1,3-oxazoline derivatives starting from 7 (31.3 mg, 
0.05 mmol), NaOH (2.4 mg, 0.06 mmol) and MeOH (1 mL). The reaction mixture was stirred at 
rt for 12 h. After standard workup, the crude was purified by flash chromatography (5:95 
MeOH/CH2Cl2) to afford compound 17 (19.6 mg, 81% yield) as a white solid. Data: Rf (1:9 
MeOH/CH2Cl2): 0.94. Mp: 77-75 ºC. [α]D + 44.3 (c 0.86, MeOH/CHCl3 2:1). FT-IR (neat) υ in cm-
1: 3320, 2918, 2849, 1736, 1579, 1468, 1379, 1229, 1161, 1030. 1H NMR (400 MHz, CD3OD) δ 
in ppm: 5.79 (d, 1H, J1,2= 7.4 Hz, H-1); 4.48 (dd, 1H, J2,1= 7.4 Hz, J2,3= 5.2 Hz, H-2); 3.78 (dd, 
1H, J6’,5= 2.8 Hz, J6’,6=12.0 Hz, H-6’); 3.73 (dd, 1H, J6’,5= 5.2 Hz, J6’,6=12.0 Hz, H-6); 3.71 (dd, 
1H, J3,2= 5.2 Hz, J3,4= 6.8, H-3); 3.48 (dd, 1H, J4,3= 6.8 Hz, J4,5= 9.0 Hz, H-4); 3.30 (m, 1H, H-5); 
3.03 (t, 2H, J= 7.6 Hz, CH2-S); 2.31 (t, 2H, J= 7.4 Hz, CH2-CO2Me); 1.72 (quint, 2H, J= 7.4 Hz, 
CH2 aliph); 1.59 (quint, 2H, J= 7.2 Hz, CH2 aliph). 1.45-1.28 (stack, 22H, CH2 aliph). 13C NMR 
(100.6 MHz, CD3OD) δ in ppm: 176.1 (C=O); 172.2 (C=N); 93.8 (C-1); 83.7 (C-2); 75.4 (C-5); 
75.0 (C-3); 69.4 (C-4); 62.9 (C-6); 34.8 (CH2-CO2H); 32.4 (CH2-S); 30.7, 30.7, 30.7, 30.6, 30.6, 
30.4, 30.2, 30.2, 29.6, 26.0 (CH2 aliph). +TOF MS Calcd for C23H41NO7S m/z [M-Na]+: 
498.2496, found: 498.2509. 
 
Inhibition studies with commercial enzymes. Inhibition constant (Ki) values were determined 
by spectrophotometrically measuring the residual hydrolytic activities of the glycosidases 
against the respective p-nitrophenyl α- or β-D-glycopyranoside, o-nitrophenyl β-D-
galactopyranoside (for β-galactosidases) or α,α’-trehalose (for trehalase) in the presence of 
compounds 12-17. Each essay was performed in phosphate buffer or phosphate-citrate buffer 
(for α- or β- mannosidase and amyloglucosidase) at the optimal pH of each enzyme. The 
reactions were initiated by addition of enzyme to a solution of the substrate in the absence or 
presence of various concentrations of inhibitor. The mixture was incubated for 10-30 min at 37 
ºC or 55 ºC (for amyloglucosidase) and the reaction was quenched by addition of 1M Na2CO3 or 
by heating and subsequent addition of a solution of GLC-Trinder (Sigma, for trehalase). 
Reaction times were appropiated to obtain 10-20% conversion of the substrate in order to 
achieve linear rates. The absorbance of the resulting mixture was determined at 405 nm or 492 
nm (for trehalase). Approximate values of Ki were determined using a fixed concentration of 
substrate (around the Km value for the different glycosidases) and various concentrations of 
inhibitor. Full Ki determinations and enzyme inhibition mode were determined from the slope of 
Lineweaver-Burk plots and double reciprocal analysis. 
 
Lysosomal enzyme activity assay. Lysosomal enzyme activities in cell lysates were 
determined as described previously [88,89]. Briefly, cells were scraped in ice-cold 0.1% Triton 
X-100 in water. After centrifugation (6,000 rpm for 15 min at 4 ºC) to remove insoluble materials, 
protein concentrations were determined using Protein Assay Rapid Kit (Wako, Tokyo, Japan). 
The lysates were incubated at 37 ºC with the corresponding 4-methylumbelliferyl β-D-
glycopyranoside solution in 0.1 M citrate buffer (pH 4). The librated 4-methylumbelliferone was 
measured with a fluorescence plate reader (exitation 340 nm; emission 460 nm; Infinite F500, 
TECAN Japan, Kawasaki, Japan). For enzyme inhibition assay, cell lysates from normal skin 
fibroblasts were mixed with the 4-methylumbelliferyl β-D-glycopyranoside substrates in the 
absence or presence of increasing concentrations of the PSO derivatives 12-17. 
 
Cell culture and GCase activity enhancement assay. Human skin fibroblasts from a healthy 
and two Gaucher disease patients (with N370S/N370S and L444P/L444P mutations) were 
maintained in our laboratory with DMEM supplemented with 10% FBS as the culture medium. 
For enzyme activity enhancement assay, cells were cultured in the presence of different 
concentrations of Glc-PSO derivatives 12 and 15 or DMSO alone (as a control) for 5 days and 
harvested by scraping [88,89]. Cytotoxicity of the compounds was monitored by measuring the 
lactate dehydrogenase activities in the cultured supernatants (LDH assay kit, Wako, Tokyo, 
Japan). 
 
Supporting information available: Experimental procedure for the preparation of methyl 16-
iodohexadecanoate and 16-iodohexadecanoic acid, NMR spectra for all new compounds and 
representative Lineweaver-Burk and double reciprocal analysis plots against β-glucosidase. 
This material is available free of charge via the Internet at http://xxxxxxxx.xxx 
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